RxDoctor Payments Data

Richard Payne, MD

Family Medicine · Encinitas, CANPI 1841252707

Payments from drug & device makers

$180,726in general payments, 2019–2025

Across 220 payments — averaging $821.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$159K
  • Astellas Pharma Europe Ltd$18K
  • AbbVie$4K
  • Lucid Diagnostics Inc.$131
  • Sanofi Pasteur Inc.$51
  • Terumo BCT, Inc.$37
  • plus $98 from 5 others

What the payments were for

  • Consulting fees$39,18722%
  • Speaking & faculty fees$99,14055%
  • Travel & lodging$36,97420%
  • Food & beverage$5,4253%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$180,726 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$133,106
Medicare patients
455
Services billed
1,731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$68,024
OzempicSemaglutide54$64,616
RybelsusSemaglutide18$34,204
TrulicityDulaglutide17$21,460
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,968
JardianceEmpagliflozin12$13,244
InvokanaCanagliflozin11$9,548
Atorvastatin Calcium711$7,305
Testosterone45$4,549
Levothyroxine Sodium242$4,179
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$3,863
Memantine Hcl43$3,536
Tamsulosin Hcl174$2,823
Losartan Potassium219$2,349
Lisinopril293$2,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$68,02460 claims
GSKTrelegy Ellipta$23$13,96819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Encinitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →